Skin Cancer

Enhancer of zeste homologue 2 overexpression was noted in cutaneous squamous cell carcinoma cases, indicating that enhancer of zeste homologue 2 had a potential role in cutaneous squamous cell carcinoma tumourigenesis.

NP at its IC50 concentration showed a stronger ability to increase the apoptotic cell rate, inhibit cancer cell migration, suppress cancer cell growth through G1-phase arrest, and increase radioprotective effects in the normal cell line, while also increasing radiosensitivity in the cancer cell line compared with PE. NP demonstrated better and more effective activity against A-375 melanoma cells than PE.

Collectively, this study systematically elucidates the toxicological mechanism by which DEHP promotes skin cancer development through subtype-specific pathways regulated by 11 key targets, clarifying its direct binding patterns with core targets and downstream pathway disruption characteristics. This not only fills a research gap in the molecular mechanisms of DEHP-induced skin carcinogenesis but also provides novel biomarkers for environmental exposure prevention and targeted interventions against skin cancer.

Most patients (80%) received the BNT162b2 (Pfizer-BioNTech) vaccine...These findings support indeed the need for continued pharmacovigilance among clinicians, especially in patients with prior or latent lymphoproliferative conditions. Nevertheless, these extremely rare and indolent events should not alter the overall favourable risk-benefit profile of COVID-19 vaccination.

LDH remains a reliable and cost-effective biomarker, while NLR may provide complementary prognostic information in patients receiving immune checkpoint inhibitors. Emerging biomarkers such as ctDNA demonstrate promising prognostic potential, but further evaluation is required before routine clinical implementation.

P=N/A, N=68, Completed, NHS Grampian | Recruiting --> Completed

P=N/A, N=464, Not yet recruiting, The University of Sydney

LILRB4 correlates strongly with macrophage infiltration, and co-expression and interaction analyses converge on antigen processing and presentation pathways, with HLA-DRA emerging as a shared node. Collectively, these findings support LILRB4 as a context-dependent marker of the myeloid and antigen-presentation axis in the tumor microenvironment and provide an integrated reference framework that warrants further functional validation.

However, further research is needed to explore its functions in other cancers and clarify its molecular mechanisms. Our review synthesizes current knowledge on CXorf67's biological significance, particularly in epigenetics and DNA damage, and its implications in oncogenesis.

P=N/A, N=140, Active, not recruiting, Centre Hospitalier Régional Metz-Thionville

In a B16 tumour-bearing mouse model, the MAuN@HA heterostructure nanozyme potently suppressed melanoma progression. Overall, this study presented a TME-responsive nanozyme strategy that combined cascade catalysis with drug release to achieve an effective ROS-amplified synergistic therapy against melanoma.

Relying exclusively on clinicopathologic factors has limitations, contributing to inconsistent use of ART in clinical settings. This systematic review highlights that the 40-GEP test improves risk stratification in cSCC and aids in making more precise ART decisions, including determining which patients may safely defer treatment.